Dual-Drug Therapy Outperforms Semaglutide Alone for Weight Loss
A combination of cagrilintide and semaglutide helped patients lose significantly more weight than semaglutide alone in a new clinical trial.
Read AnalysisTirzepatide Beats Semaglutide for Faster, Greater Weight Loss
A massive new real-world study reveals that tirzepatide delivers faster and more significant weight loss with fewer side effects than semaglutide.
Read AnalysisNew Duo Drug CagriSema Shows Dramatic Results for Diabetes
A dual-action weekly injection called CagriSema drastically lowers blood sugar and body weight in adults with early-stage type 2 diabetes.
Read AnalysisTirzepatide Beats Standard Care for Early Type 2 Diabetes
A landmark clinical trial shows tirzepatide achieves superior blood sugar control and health markers compared to conventional diabetes treatments.
Read AnalysisNew Dual-Action Drug Outperforms Semaglutide in Diabetes Trial
A new combination therapy called CagriSema shows superior blood sugar control compared to semaglutide alone in a major phase 3 clinical trial.
Read AnalysisAn Oral Pill Helps Maintain Weight Loss After Injectables
A new clinical trial shows a daily oral medication can help prevent weight regain after stopping weekly injectables.
Read AnalysisSemaglutide Significantly Slows Biological Aging, Clinical Trial Shows
A breakthrough study reveals that semaglutide can significantly reverse markers of biological and cellular aging.
Read AnalysisPopular Diabetes Drugs Linked to Better Breast Cancer Survival
A massive retrospective study suggests that GLP-1 receptor agonists may dramatically lower mortality and recurrence rates for breast cancer patients with obesity or type 2 diabetes.
Read AnalysisSemaglutide May Boost Motivation in People With Depression
A new clinical trial suggests semaglutide could help overcome the paralyzing lack of motivation often caused by major depressive disorder.
Read Analysis